Stockscreener 앱 받기
3.97
0.51%
0.02
시간 외 거래:
3.99
0.02
+0.50%
전일 마감가:
$3.95
열려 있는:
$3.91
하루 거래량:
202.03K
Relative Volume:
0.51
시가총액:
$41.02M
수익:
$21.73M
순이익/손실:
$-91.17M
주가수익비율:
-5.3649
EPS:
-0.74
순현금흐름:
$-286.43M
1주 성능:
-5.25%
1개월 성능:
-19.80%
6개월 성능:
-56.12%
1년 성능:
-77.94%
1일 변동 폭
$3.81
$4.00
1주일 범위
$3.81
$4.24
52주 변동 폭
$3.56
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
명칭
Bluebird Bio Inc
전화
339-499-9300
주소
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
BLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
3.97 | 41.02M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-11-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-11-15 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-08-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-12-11 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2023-12-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-19 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-28 | 개시 | JP Morgan | Overweight |
| 2023-03-07 | 개시 | Robert W. Baird | Outperform |
| 2022-08-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-07 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-11-08 | 재확인 | Barclays | Equal Weight |
| 2021-11-08 | 재확인 | Canaccord Genuity | Hold |
| 2021-11-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-11-08 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | 재확인 | Wedbush | Neutral |
| 2021-11-08 | 재확인 | Wells Fargo | Equal Weight |
| 2021-08-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-08-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | 재개 | William Blair | Mkt Perform |
| 2021-08-09 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-03-10 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-02-17 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-02-16 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-11-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-11-02 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | 개시 | Mizuho | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-27 | 업그레이드 | Stifel | Hold → Buy |
| 2020-02-19 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | 재개 | BofA/Merrill | Buy |
| 2020-02-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-10-01 | 개시 | Stifel | Hold |
| 2019-08-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | 업그레이드 | Maxim Group | Hold → Buy |
모두보기
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
Carlyle And Sk Capital Receive All Required Regulatory Approvals To Complete The Acquisition Of Bluebird Bio - marketscreener.com
bluebird bio nears acquisition by Carlyle and SK Capital - Investing.com
Bluebird Bio (BLUE) Nears Acquisition Completion Following Regulatory Approvals | BLUE Stock News - GuruFocus
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - Yahoo Finance
Investors Who Lost Money on Bluebird Bio, Inc. (BLUE) Should Contact Levi & Korsinsky About Pending Class Action – BLUE - ACCESS Newswire
Halper Sadeh LLP, bluebird bio, Inc., Walgreens Boots Alliance, Chimerix, Inc. - Olean Times Herald
Sickle Cell Disease Treatment Market Set to Witness Significant - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Cell And Gene Therapy Manufacturing Market Is Booming So Rapidly 2025-2032 -Bluebird Bio Inc., Lonza, Catalent Inc. - openPR.com
Gene Therapy Market Statistics 2025-2033 | Regional Breakdown & - openPR.com
Lost Money on bluebird bio, Inc.(BLUE)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - ACCESS Newswire
Most US states OK Medicaid pilot for sickle cell gene therapies - The Boston Globe
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Gene Therapy For Rare Disease Market Set to Witness Significant - openPR.com
Drug and Gene Delivery Devices Market Future Business - openPR.com
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline - Yahoo Finance
bluebird bio opts to stay with Carlyle/SK takeover offer - The Pharma Letter
Bluebird says Ayrmid missed deadline for rival takeover bid - BioPharma Dive
bluebird bio's board opts for sale to U.S. investment firms - The Business Journals
Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid - marketscreener.com
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer - BioSpace
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird - Endpoints News
bluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's Uncertaint - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - BioSpace
Bluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock Fell - Nasdaq
Bluebird bio shares fall amid acquisition woes - Investing.com Australia
Bluebird bio shares fall amid acquisition woes By Investing.com - Investing.com Canada
Tesla, Cal-Maine Foods, Bluebird Bio - TradingView
Bluebird Bio falls after Ayrmid fails to give binding offer - TradingView
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9% - MSN
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquis - GuruFocus
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquisition Deal | BLUE Stock News - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement | BLUE Stock News - GuruFocus
Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement - marketscreener.com
bluebird bio backs Carlyle and SK Capital takeover bid - Investing.com
Gene Therapy Market Insights 2025Trends, Growth Forecast & - openPR.com
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
Sickle Cell Disease Treatment Market to Hit $7.04 Billion By 2032 - openPR.com
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire
Bluebird Bio Inc (BLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):